Innova Captab Ltd (INNOVACAP) — shareholding pattern, promoter holding, financials and share price
About Innova Captab Ltd (INNOVACAP)
Innova Captab Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as INNOVACAP and on the BSE under scrip code 544067. Its ISIN is INE0DUT01020.
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain. [1]
Innova Captab Limited is an integrated pharmaceutical company engaged in CDMO services, as well as domestic and international branded generics. It operates comprehensive manufacturing units producing various dosage forms across multiple therapeutic areas.
The company has shown a robust financial performance with a 42% YoY revenue growth in Q3 FY26, driven by accelerated expansion in both CDMO and branded generics sectors, particularly with substantial contributions from its Jammu facility.
Listed peers in Pharmaceuticals: Senores Pharmaceuticals Ltd, Aarti Pharmalabs Ltd, Bliss GVS Pharma Ltd, Orchid Pharma Ltd, IOL Chemicals & Pharmaceuticals Ltd, Zota Health Care Ltd.
Valuation & Returns
10 Jul 2026At ₹989.45 a share on 10 Jul 2026, Innova Captab Ltd (INNOVACAP) was valued at a price-to-earnings ratio of 40.18x against an industry P/E of 36.41x and a price-to-book of 5.19x on a book value of ₹190.61 per share as of Mar 2026. Solomo computes return on equity of 12.92% and return on capital employed of 14.3% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 40.18x
- Industry P/E
- 36.41x
- P/B
- 5.19x
- EPS (TTM)
- ₹24.63
- Book value / share
- ₹190.61
- ROE
- 12.92%
- ROCE
- 14.3%
- ROA
- 7.67%
- Debt / equity
- 0.32x
- Dividend yield
- 0.2%
- EBITDA margin
- 15.36%
- 52-week range
- ₹608.25 – ₹1,032
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Innova Captab Ltd (INNOVACAP) reported revenue of ₹1,630 crore, net profit of ₹141 crore and earnings per share of ₹24.63. That compares with revenue of ₹1,244 crore and net profit of ₹128 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹448 crore and net profit ₹38 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 801 | 926 | 1,081 | 1,244 | 1,630 |
| Net profit (₹ cr) | 64 | 68 | 94 | 128 | 141 |
| EPS (₹) | 532.92 | 14.16 | 16.49 | 22.41 | 24.63 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 25.90% | 14.79% | 31.06% |
| Profit growth | 19.39% | 13.29% | 9.87% |
| Stock price CAGR | - | - | 12% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 50.9% of Innova Captab Ltd (INNOVACAP) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.34% and domestic institutional investors (DII) hold 19.92%. Market capitalisation was ₹5,662 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2023.
Largest disclosed public shareholders in Jun 2026: GIAN PARKASH AGGARWAL 10.8%, ARCHIT AGGARWAL 8.74%, KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK MULTICAP F 3.64%, CANARA ROBECO MUTUAL FUND A/C CANARA ROBECO SMALL 3.61%, CLARUS CAPITAL I 3.58%, 360 ONE SPECIAL OPPORTUNITIES FUND - SERIES 9 2.05%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 50.9% | - | 0.34% | 19.92% | 49.1% |
| Mar 2026 | 50.9% | - | 0.23% | 20.14% | 49.1% |
| Dec 2025 | 50.9% | - | 0.11% | 20.24% | 49.1% |
| Sep 2025 | 50.9% | - | 0.08% | 20.17% | 49.1% |
| Jun 2025 | 50.9% | - | 0.23% | 19.67% | 49.1% |
| Mar 2025 | 50.9% | - | 0.34% | 19.76% | 49.1% |
| Dec 2024 | 50.9% | - | 0.74% | 19.96% | 49.1% |
| Sep 2024 | 50.9% | - | 1.01% | 20.61% | 49.1% |